Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
endTB Observational Study had sites in 17 countries. In each country, sites enrolled patients on treatment with bedaquiline and delamanid according to National TB Program guidelines, ...
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Pharmacovigilance forms and other resources for staff on endTB sites.
The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.
It provides advice to any MSF, PIH and IRD pro...
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...
This guide is designed to give guidance to the endTB Project site on the use of new TB drugs bedaquiline and delamanid. It is intended to be a resource for physicians and other health...
This document is designed to give guidance to the endTB Project sites on the response to the COVID-19 outbreak. It is intended to be a resource for physicians and other health care pr...
Researchers from endTB participated in the WHO Global Consortium to share updated results and the study’s implementation practices, in addition to evidence to support the transition, ...
This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.